Patients with rheumatoid arthritis who switched biologics incurred higher costs than patients who persisted on biologics. Etanercept appeared to be associated with the lowest costs.
Alex Mutebi, PhD
Advertisement
Articles by Alex Mutebi, PhD
This review assesses the current molecular testing landscape for non–small-cell lung cancer in the United States.
Advertisement
Latest Updated Articles
- Reimbursement Landscape for Molecular Testing in Non-Small Cell Lung Cancer
Published: February 20th 2018 | Updated:
- eAppendix
Published: February 17th 2018 | Updated:
- Cost of Biologic Treatment Persistence or Switching in Rheumatoid Arthritis
Published: July 12th 2018 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
Real-World Data Support Dual Benefit of Biologic Therapy for Hidradenitis Suppurativa
2
ERS Posters Showcase Nerandomilast Benefits in IPF, ILD
3
Bringing Advanced Cancer Care Closer to Patients Improves Access, Equity: Kathy Oubre, MS
4
First-in-Class Rocatinlimab Aims to Rebalance T Cells in Atopic Dermatitis: Emma Guttman, MD, PhD
5
